Suppr超能文献

芽殖相关 Ena/血管扩张刺激磷蛋白同源 1 结构域蛋白 (SPRED1),是 Ras/细胞外信号调节激酶 (ERK) 通路中酪氨酸蛋白磷酸酶非受体型 11 (SHP2) 的底物。

Sprouty-related Ena/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the Ras/extracellular signal-regulated kinase (ERK) pathway.

机构信息

Institute of Molecular and Cell Biology, Signal Transduction Laboratory, 61 Biopolis Drive, Proteos 138673, Singapore.

出版信息

J Biol Chem. 2011 Jul 1;286(26):23102-12. doi: 10.1074/jbc.M110.212662. Epub 2011 Apr 29.

Abstract

SHP2 is a tyrosine phosphatase involved in the activation of the Ras/ERK signaling pathway downstream of a number of receptor tyrosine kinases. One of the proposed mechanisms involving SHP2 in this context is to dephosphorylate and inactivate inhibitors of the Ras/ERK pathway. Two protein families bearing a unique, common domain, Sprouty and SPRED proteins, are possible candidates because they have been reported to inhibit the Ras/ERK pathway upon FGF activation. We tested whether any of these proteins are likely substrates of SHP2. Our findings indicate that Sprouty2 binds to the C-terminal tail of SHP2, which is an unlikely substrate binding site, whereas SPRED proteins bind to the tyrosine phosphatase domain that is known to be the binding site for its substrates. Overexpressed SHP2 was able to dephosphorylate SPREDs but not Sprouty2. Finally, we found two tyrosine residues on SPRED1 that are required, when phosphorylated, to inhibit Ras/ERK activation and identified Tyr-420 as a specific dephosphorylation target of SHP2. The evidence obtained indicates that SPRED1 is a likely substrate of SHP2, whose tyrosine dephosphorylation is required to attenuate the inhibitory action of SPRED1 in the Ras/ERK pathway.

摘要

SHP2 是一种酪氨酸磷酸酶,参与多种受体酪氨酸激酶下游 Ras/ERK 信号通路的激活。在这种情况下涉及 SHP2 的一种假设机制是通过去磷酸化和失活 Ras/ERK 通路的抑制剂。两个具有独特共同结构域的蛋白家族,Sprouty 和 SPRED 蛋白,是可能的候选者,因为它们已被报道在 FGF 激活时抑制 Ras/ERK 通路。我们测试了这些蛋白中是否有任何一个是 SHP2 的可能底物。我们的研究结果表明,Sprouty2 与 SHP2 的 C 末端尾巴结合,这是一个不太可能的底物结合位点,而 SPRED 蛋白结合到已知是其底物结合位点的酪氨酸磷酸酶结构域。过表达的 SHP2 能够使 SPRED 去磷酸化,但不能使 Sprouty2 去磷酸化。最后,我们发现 SPRED1 上的两个酪氨酸残基在磷酸化时需要抑制 Ras/ERK 激活,并鉴定出 Tyr-420 是 SHP2 的一个特异性去磷酸化靶标。获得的证据表明,SPRED1 是 SHP2 的一个可能底物,其酪氨酸去磷酸化是减弱 SPRED1 在 Ras/ERK 通路中的抑制作用所必需的。

相似文献

3
5
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival.
Dev Cell. 2006 Mar;10(3):317-27. doi: 10.1016/j.devcel.2006.01.002.
7
Regulation of the mitogen-activated protein kinase signaling pathway by SHP2.
J Biol Chem. 2002 Mar 15;277(11):9498-504. doi: 10.1074/jbc.M110547200. Epub 2002 Jan 4.

引用本文的文献

2
Legius syndrome mutations in the Ras-regulator SPRED1 abolish its membrane localization and potentially cause neurodegeneration.
J Biol Chem. 2024 Dec;300(12):107969. doi: 10.1016/j.jbc.2024.107969. Epub 2024 Nov 5.
4
Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Leukemia. 2021 Aug;35(8):2285-2298. doi: 10.1038/s41375-021-01166-9. Epub 2021 Feb 15.
5
Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2.
J Biol Chem. 2020 May 1;295(18):6187-6201. doi: 10.1074/jbc.RA119.010274. Epub 2020 Mar 18.
6
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling.
Front Immunol. 2019 Oct 25;10:2468. doi: 10.3389/fimmu.2019.02468. eCollection 2019.
7
The Sprouty/Spred family as tumor suppressors: Coming of age.
Cancer Sci. 2019 May;110(5):1525-1535. doi: 10.1111/cas.13999. Epub 2019 Apr 23.

本文引用的文献

2
Sprouty proteins: modified modulators, matchmakers or missing links?
J Endocrinol. 2009 Nov;203(2):191-202. doi: 10.1677/JOE-09-0110. Epub 2009 May 7.
3
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.
Cell Signal. 2008 Mar;20(3):453-9. doi: 10.1016/j.cellsig.2007.10.002. Epub 2007 Oct 11.
4
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.
Nat Genet. 2007 Sep;39(9):1120-6. doi: 10.1038/ng2113. Epub 2007 Aug 19.
5
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Nat Genet. 2007 Aug;39(8):1007-12. doi: 10.1038/ng2073. Epub 2007 Jul 1.
6
Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Nat Genet. 2007 Aug;39(8):1013-7. doi: 10.1038/ng2078. Epub 2007 Jul 1.
8
Protein tyrosine phosphatase function: the substrate perspective.
Biochem J. 2007 Feb 15;402(1):1-15. doi: 10.1042/BJ20061548.
9
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.
Nat Genet. 2007 Jan;39(1):75-9. doi: 10.1038/ng1939. Epub 2006 Dec 13.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验